Tag Archives: Strategy

CEO Interview: Harvey Berger, Ariad Pharmaceuticals

Eight months into the launch of its first approved drug – Iclusig (ponatinib), a small molecule therapy indicated for two rare forms of leukemia – Ariad Pharmaceuticals’ principal founder and CEO Harvey Berger says doing it all, from discovery to global commercialization, is the company’s path to sustainability and the way to take on Big […]
Posted in Biotech, Europe, Gene therapy, Global, leadership, Market Access, Marketing, pricing, R&D, Regulatory, Safety, Sales, Strategy, Technology | Also tagged , , , , , , , , | Leave a comment

"Series A Crunch"? Some Suggestions

Recently, there has been an uptick in newsflow around the “series A crunch”/ “the valley of death” in regards to financing. Because of who we are (a firm that connects investors with private equity investments); we at Poliwogg see a lot of the “crunched” and “valley-dwellers.” We have some good news. The good news is […]
Posted in Guest Blog, Strategy | Also tagged , , | Leave a comment

Mapping Opportunities with the Non-Physician Prescriber

They write 92% of their prescriptions without consulting a physician and are often the first provider a patient sees, and yet nurse practitioners, physician’s assistants and other non-physician prescribers (NPPs) are still somehow overlooked by pharma as an opportunity to drive sales. A GSW Worldwide report titled The non-physician prescriber will see you now points […]
Posted in Advertising, compliance, healthcare, Marketing, Patient Communication, patient compliance, patient education, Sales, Strategy | Also tagged , , , , , , , , , , , | Leave a comment

Pipeline Report Preview

Posted in Advertising, Biotech, Europe, FDA, Gene therapy, Global, IP, R&D, Regulatory, Strategy, Video | Also tagged , , , , , , , , | Leave a comment

Clayton Christensen on the Future of Pharma

A keynote speaker at the 9thAnnual SaS Health Care & Life Sciences Executive Conference on May 10, ‘disruptive’ author of The Innovator’s Dilemma and Harvard business professor Clayton Christensen sat down with PharmExec to discuss the future of the pharmaceutical industry, and what Mitt Romney could bring to the White House.
Posted in Biotech, Events, FDA, healthcare, IP, leadership, People, R&D, Regulatory, Safety, Technology, Uncategorized | Also tagged , , , , , , , , , , , | 1 Comment
  • Categories

  • Meta